Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.

@article{Kondo2004EfficacyAS,
  title={Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.},
  author={Hirobumi Kondo and Toru Abe and Hiroshi Hashimoto and Shoji Uchida and Shoichiro Irimajiri and Masako Hara and Sachiko Sugawara},
  journal={The Journal of rheumatology},
  year={2004},
  volume={31 2},
  pages={243-51}
}
OBJECTIVE To evaluate the efficacy and safety of tacrolimus (FK506) in patients with active rheumatoid arthritis (RA) exhibiting resistance to disease modifying antirheumatic drug (DMARD) therapy, and to determine the optimal dosage. METHODS A total of 212 patients with DMARD-resistant RA were enrolled in this double blind, multicenter, randomized, placebo controlled study and allocated to 3 groups. Patients were administered tacrolimus at a dosage of 1.5 mg/day (68 patients) or 3 mg/day (70… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…